Klow Peptide Dose Per Day for Females

Klow is a compounded peptide blend marketed primarily to female patients for weight loss, appetite control, and skin quality. The name is not a chemical designation. It is a brand label used by a handful of specialty compounding pharmacies to package two to four peptides into a single vial. The most common formulations include a KPV fraction, a weight-loss component (AOD-9604 or tesofensine), and sometimes a third lipolytic or anti-inflammatory ingredient.

The marketing targets women because the dose ranges, the timing, and the expected outcomes (appetite suppression plus gut-level inflammation reduction plus modest fat loss) map onto concerns that show up more often in female patients asking about peptides. The actual pharmacology is not sex-specific. KPV, an alpha-MSH-derived tripeptide, blocks NF-kB and MAP kinase signaling at nanomolar concentrations via PepT1-mediated uptake into intestinal epithelial and immune cells (Dalmasso et al., 2008). AOD-9604 (the hGH 177-191 fragment) mimics the lipolytic activity of growth hormone without the diabetogenic effects (Heffernan et al., 2001), and tesofensine inhibits reuptake of dopamine, noradrenaline, and serotonin (Astrup et al., 2008). All three work the same way in male and female tissue. The "female" framing in Klow is a dosing convention, not a biological requirement.

The most common Klow variant, Klow-80, contains KPV plus AOD-9604 plus a proprietary "slimfit" fraction that most pharmacies describe as a short chain lipolytic peptide. Some pharmacies substitute tesofensine for AOD-9604 in patients who need stronger appetite control. A few variants add LL-37 for mast cell stabilization. You will not find two Klow vials with the same ingredient ratios across pharmacies, which is why a universal dose chart does not exist.

Klow is not FDA-approved. The individual peptides inside Klow are not FDA-approved for weight loss either. Compounded peptide blends fall under state pharmacy regulations, which means quality, sterility, and potency vary widely. For the legal framework around compounded peptides, see are peptides legal and the compounded tirzepatide safety analysis.

The dosing conventions below are drawn from protocols published by specialty compounding pharmacies that sell Klow blends. They are not clinical guidelines. No published randomized trial of Klow exists.

KPV fraction (anti-inflammatory, appetite regulation): - Starting dose: 200 mcg once daily - Target dose: 250 to 400 mcg once daily - Upper range: 500 mcg daily, split morning and evening if oral - Route: typically subcutaneous in the Klow blend, sometimes oral as a separate component

AOD-9604 fraction (lipolysis, fat oxidation): - Starting dose: 100 mcg once daily - Target dose: 200 to 300 mcg once daily - Route: subcutaneous, morning on empty stomach for best lipolytic effect

Tesofensine fraction (appetite suppression, dopamine noradrenaline reuptake inhibitor): - Starting dose: 100 mcg daily (oral drops or subcutaneous depending on compound) - Target dose: 250 to 500 mcg daily (the 0.5 mg dose produced 9.2% mean weight loss at 24 weeks vs 2.0% on placebo in the phase 2 trial; (Astrup et al., 2008)) - Upper range: 750 mcg; above this most women report insomnia, elevated heart rate, and anxiety

Lipolytic or "slimfit" fraction (varies by pharmacy): - Typical dose: 0.25 to 0.5 mg daily - Usually a proprietary blend; ask for ingredient disclosure

For most 130 to 145-pound women starting Klow for weight loss, a reasonable first-month protocol is 250 mcg KPV plus 150 mcg AOD-9604 daily, 5 days on and 2 days off, titrating up after 4 weeks if tolerated. See the KPV peptide dosage guide for the KPV-specific ramp schedule and the glow peptide dosage guide for a comparable female-focused blend.

The "80" in Klow-80 usually refers to the combined peptide concentration per milliliter after reconstitution (roughly 8 mg/mL total), not a standardized recipe. Common published ratios from compounding pharmacies:

Reconstitution matters more than the chart. A 10 mg total peptide vial reconstituted in 2 mL of bacteriostatic water gives a different concentration than the same vial in 1 mL. One unit on a U-100 insulin syringe equals 0.01 mL. If your pharmacy reconstituted a Klow-80 vial with 2 mL, then 10 units delivers approximately 400 mcg of total peptide blend.

Standard reconstitution math for Klow-80 (10 mg total peptide): - 1 mL bacteriostatic water: 10 units = 1,000 mcg total blend - 2 mL bacteriostatic water: 10 units = 500 mcg total blend - 3 mL bacteriostatic water: 10 units = 333 mcg total blend

Never guess. Use the peptide reconstitution calculator with your vial's actual mg and reconstitution volume before your first injection. For injection technique, site rotation, and needle selection, see how to inject peptides.

Morning is the default window for Klow. The AOD-9604 fraction works best on an empty stomach because post-meal insulin blunts lipolysis. The tesofensine fraction (where present) acts as a stimulant; evening dosing causes insomnia in most users. KPV has no timing preference from a systemic standpoint but pairs well with morning dosing when blended with the other two.

The standard Klow protocol for female weight loss: - 6:30 to 7:30 AM: inject Klow subcutaneously in the lower abdomen or upper thigh - 7:30 to 8:30 AM: light breakfast with protein (25 to 30 g) - Do not inject within 30 minutes of coffee or a high-sugar meal - Rotate injection sites every day to avoid lipohypertrophy

Why 5 days on, 2 days off: most compounding pharmacies recommend weekday dosing with a weekend washout. The rationale is to prevent receptor downregulation on the melanocortin pathway (KPV) and the adrenergic pathway (tesofensine). Clinical evidence for this schedule is thin, but anecdotal reports from practitioners suggest fewer side effects and cleaner appetite signaling with the 5-on, 2-off pattern.

Food interactions: avoid grapefruit, high-acid beverages, and heavy carbohydrate meals within 60 minutes of the injection. Grapefruit inhibits CYP3A4 and may prolong tesofensine half-life. High-acid drinks can destabilize the KPV tripeptide bond. Heavy carb meals blunt AOD-9604 lipolysis. For broader peptide timing principles, see our KPV peptide morning or night guide.

Do not inject Klow within 30 minutes of a hot shower, sauna, or intense cardio. Vasodilation speeds distribution and can produce flushing, dizziness, or a brief heart rate spike.

Klow tolerance varies. Some women feel appetite suppression on day three; others need the full 4-week ramp. The protocol below is a conservative starting schedule for a 130 to 150-pound female patient using a Klow-80 Formula A blend.

Weeks 1 to 2 (assessment phase): - Dose: 150 mcg total peptide blend daily (roughly 3 to 4 units at 2 mL reconstitution) - Goal: confirm tolerance. Watch for injection site reactions, nausea, elevated heart rate, sleep disruption - Do not increase if you notice any side effect; hold at the starting dose

Weeks 3 to 4 (titration): - Dose: 250 mcg total peptide blend daily (roughly 5 to 6 units) - Goal: appetite suppression should appear by day 10 to 14. Mild weight loss (1 to 2 pounds per week) is normal

Weeks 5 to 8 (target phase): - Dose: 400 mcg total peptide blend daily (roughly 8 to 10 units) - Goal: consistent appetite control, steady fat loss at 0.5 to 1 percent body weight per week - Track: waist circumference, resting heart rate, sleep quality, and menstrual cycle regularity

Weeks 9 to 12 (plateau or maintenance): - Dose: hold at 400 mcg or titrate to 500 mcg if tolerated - Goal: maintain weight loss trajectory or transition to maintenance dosing - Consider a 4-week break after week 12 to reset receptor sensitivity

Women with lower body weight (under 120 pounds) should start at 100 mcg total blend and titrate slower. Women over 170 pounds may need the upper range (600 to 800 mcg total blend) but should first rule out whether a single-agent GLP-1 analogue would be more appropriate. For structural stacking principles, see our peptide stacking guide and the wolverine peptide stack for a contrast with male-focused blends.

Most Klow side effects come from the tesofensine or AOD-9604 fractions, not the KPV component. KPV itself has a clean safety profile at these doses. The appetite suppressant and lipolytic fractions carry the real watch list.

Common and usually self-limiting: - Injection site redness or mild bruising (rotate sites) - Dry mouth, especially with tesofensine - Mild nausea in week 1 (usually resolves by day 10) - Transient fatigue 2 to 4 hours after injection - Minor menstrual cycle shifts (one to three days later, rarely earlier)

Call your prescriber (not 911) if you notice: - Resting heart rate persistently above 95 bpm - Sleep onset delayed by more than 90 minutes three nights running - Anxiety or panic attacks (more common with tesofensine) - Severe appetite suppression leading to intake below 1,200 calories daily - Persistent dizziness on standing - Amenorrhea lasting more than one cycle

Stop immediately and call a doctor if: - Chest pain or palpitations lasting more than 10 minutes - Fainting or near-fainting episodes - Severe abdominal pain - Signs of allergic reaction (hives, swelling, difficulty breathing) - Unexpected pregnancy (Klow has unknown effects on fetal development; no safety data exists)

Red flags for female-specific concerns: - Do not use Klow during pregnancy or while trying to conceive. None of the peptides in Klow have reproductive safety data in humans. - Do not use Klow while breastfeeding. Peptide excretion into breast milk is not characterized. - If you have a history of eating disorders, the appetite suppression from Klow can trigger a relapse. Talk to a provider before starting. - If you have a history of cardiac arrhythmia, avoid tesofensine-containing Klow variants.

For a broader safety framework when choosing peptides, see peptides for women over 40 and the general peptide dosage chart.

Klow is one of several branded peptide blends marketed through compounding pharmacies. The closest alternatives differ in their target outcomes and their peptide ratios.

Klow vs Glow: Glow is the skin-and-repair blend (GHK-Cu plus BPC-157 plus TB-500 in most formulations). Klow is the weight-loss-plus-gut blend (KPV plus AOD-9604 or tesofensine). They are complementary, not competitive. Many female patients run Klow in the morning and Glow in the evening. For Glow specifics, see the glow peptide dosage guide.

Klow vs Wolverine: Wolverine is the male-focused recovery stack (BPC-157 plus TB-500 plus GHK-Cu, sometimes with IGF-1 LR3). Klow's female orientation is about weight and appetite rather than muscle recovery. Dose ranges are lower in Klow because the target tissues are different. See the wolverine peptide stack for comparison.

Klow vs single-agent KPV: if you only want anti-inflammatory and gut benefits, single-agent KPV at 250 to 500 mcg daily is cheaper, better studied, and avoids the stimulant fraction. Klow makes sense when you want appetite suppression plus anti-inflammation in one injection. Read the KPV peptide dosage guide before deciding.

Klow vs GLP-1 (semaglutide, tirzepatide): for weight loss targets above 20 pounds, a GLP-1 receptor agonist has orders of magnitude more clinical evidence. Klow is a lighter intervention suited to patients who want 5 to 15 pounds of loss plus gut and skin benefits. For heavier weight loss, the GLP-1 path is more appropriate; see our compounded tirzepatide safety analysis.

Use the peptide stack calculator to check interactions before combining Klow with any other peptide or GLP-1.